Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience

Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience

IntroductionTyrosine kinase inhibitor (TKI) therapy has greatly improved the prognosis of patients with chronic myeloid leukemia (CML), improving the survival expectancy of patients with chronic phase (CP) CML to that of the general population. However, despite these advances, nearly 50% of patients...

Full description

Bibliographic Details
Main Authors: Tamara Chitanava, Iuliia Matvienko, Vasily Shuvaev, Sergey Voloshin, Irina Martynkevich, Yulia Vlasova, Elizaveta Efremova, Ekaterina Mileeva, Anna Pirkhalo, Taiana Makarova, Roman Vlasik, Elena Karyagina, Natalia Il`ina, Nadezhda Medvedeva, Natalia Dorofeeva, Tatiana Shneider, Nadia Siordiya, Olga Kulemina, Evgenia Sbityakova, Natalia Lazorko, Julia Alexeeva, Dmitrii Motorin, Elena Morozova, Elza Lomaia
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Oncology
Subjects:
chronic myeloid leukemia
chronic phase
efficacy of therapy
complete cytogenetic response
third-line therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1138683/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1138683/full

Similar Items